Related Experiment Videos
Central sleep apnoea and heart failure (Part I)
1Department of Critical Care, Manly Hospital, New South Wales, Australia.
Respirology (Carlton, Vic.)
|April 3, 1998
Summary
Central sleep apnoea (CSA) in heart failure is a poor prognostic sign. Treatments like nasal CPAP may improve ejection fraction and prognosis, potentially breaking a harmful cycle.
Area of Science:
- Cardiology
- Sleep Medicine
- Pulmonology
Background:
- Central sleep apnoea (CSA) is linked to congestive heart failure (CHF) and left ventricular dysfunction.
- CSA in CHF is sleep-dependent, requiring hypocapnia and prolonged circulation time.
- The prognostic significance of CSA in CHF with left ventricular dysfunction is poorly understood.
Observation:
- CSA in CHF is associated with higher mortality compared to CHF alone.
- CSA may create a detrimental cycle of increased afterload and reduced ejection fraction.
- Treatments including oxygen, acetazolamide, and nasal CPAP reduce CSA.
Findings:
- Nasal CPAP therapy significantly improves ejection fraction in CHF patients with CSA.
- Improvements in ejection fraction persist post-treatment, suggesting cardiac remodeling or sympathetic nervous system resetting.
- A 35% average increase in ejection fraction was observed after three months of nasal CPAP.
Implications:
- Nasal CPAP offers a promising therapeutic strategy for CHF patients with CSA.
- Improved ejection fraction may lead to better prognosis in this patient group.
- Further global replication of these findings is needed to confirm efficacy.